LOUVAIN-LA-NEUVE, Belgium, July 16, 2014 /CNW/ - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces that it has received Marketing Authorization from the U.S. Food and Drug Administration (FDA) for its Compact Gantry Beam Line (CGBL: FDA 510(k) K132919). IBA anticipates that this regulatory approval will intensify the international interest in Proteus®ONE*, IBA's next generation proton therapy compact system.
To view the Multimedia News Release, please click:
Proteus®ONE is IBA's single-room proton therapy system which is smaller, less expensive, faster to install and encompasses the latest in targeted proton therapy technologies, including IBA's Intensity Modulated Proton Therapy (IMPT). IBA created the Proteus®ONE system to allow more patients access to proton therapy globally and has already sold five Proteus®ONE systems in Shreveport, Louisiana (USA), Nice (France), Taiwan (China) and two in Japan.
* Proteus®ONE is the brand name of a new configuration of the Proteus® 235.
SOURCE: IBA sa
For further information: Chemin du Cyclotron, 3 | 1348 Louvain-la-Neuve | Belgium | Tel.: + 32-10-47-58-11 | Fax: + 32-10-47-58-10 | E-mail: email@example.com